RxSight, Inc. (RXST) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RXST Revenue Growth
Revenue Breakdown (FY 2025)
RXST's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
RXST Revenue Analysis (2019–2025)
As of May 8, 2026, RxSight, Inc. (RXST) generated trailing twelve-month (TTM) revenue of $127.5 million, reflecting significant decline in growth of -18.5% year-over-year. The most recent quarter (Q1 2026) recorded $30.9 million in revenue, down 5.3% sequentially.
Looking at the longer-term picture, RXST's 5-year compound annual growth rate (CAGR) stands at +55.7%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $139.9 million in 2024.
Revenue diversification analysis shows RXST's business is primarily driven by RxLAL (80%), L D D (15%), and Service Warranty Service Contracts And Accessories (4%). With over half of revenue concentrated in RxLAL, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including LMAT (+13.3% YoY), ATRC (+15.0% YoY), and IRTC (+27.4% YoY), RXST has underperformed the peer group in terms of revenue growth. Compare RXST vs LMAT →
RXST Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RXSTCurrent | $127M | -18.5% | +55.7% | -35.8% | |
 LMAT | $250M | +13.3% | +14.0% | 27.2% | |
 ATRC | $535M | +15.0% | +20.9% | -0.6% | |
 IRTC | $747M | +27.4% | +23.0% | -4.9% | |
 TMDX | $605M | +30.2% | +88.2% | 17.9% | |
 ALGN | $4.0B | +2.9% | +10.3% | 15.3% |
RXST Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $134.5M | -3.9% | $103.0M | 76.6% | $-48,190,000 | -35.8% |
| 2024 | $139.9M | +57.1% | $98.9M | 70.7% | $-36,858,000 | -26.3% |
| 2023 | $89.1M | +81.8% | $53.8M | 60.4% | $-50,085,000 | -56.2% |
| 2022 | $49.0M | +116.9% | $21.3M | 43.5% | $-63,318,000 | -129.2% |
| 2021 | $22.6M | +53.9% | $4.5M | 20.0% | $-52,787,000 | -233.6% |
| 2020 | $14.7M | +555.0% | $1.7M | 11.6% | $-35,405,000 | -241.2% |
| 2019 | $2.2M | - | $-1,819,000 | -81.2% | $-46,070,000 | -2055.8% |
See RXST's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RXST Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RXST vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRXST — Frequently Asked Questions
Quick answers to the most common questions about buying RXST stock.
Is RXST's revenue growth accelerating or slowing?
RXST revenue declined -18.5% year-over-year, contrasting with the 5-year CAGR of +55.7%. TTM revenue fell to $127M. This reverses the prior growth trend.
What is RXST's long-term revenue growth rate?
RxSight, Inc.'s 5-year revenue CAGR of +55.7% reflects the variable expansion pattern. Current YoY growth of -18.5% is below this long-term average.
How is RXST's revenue distributed by segment?
RXST reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.